INFI - Infinity Pharmaceuticals EPS beats by $0.01 beats revenue; issues guidance

Infinity Pharmaceuticals (INFI): Q2 GAAP EPS of -$0.13 beats by $0.01.Royalty revenue of $0.51M (+41.7% Y/Y) beats by $0.27MAt June 30, 2021, Infinity had total cash, cash equivalents and available-for-sale securities of $97.3M, compared to $106.8M at March 31, 2021.Financial Outlook:  Infinity expects net loss for 2021 to range from $40 million to $50 million and expects to end 2021 with a year-end-cash, cash equivalents and available for sale securities balance ranging from $70 million to $80 million.Press Release

For further details see:

Infinity Pharmaceuticals EPS beats by $0.01, beats revenue; issues guidance